Loading…

Loading grant details…

Completed HORIZON European Commission

A novel non-invasive therapy based on injectable viscous gel for restoring the natural biomechanics of the spine and relieving patients from pain

€5.22M EUR

Funder European Commission
Recipient Organization Nc Biomatrix Bv
Country Netherlands
Start Date Jun 01, 2023
End Date Sep 30, 2025
Duration 852 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190168073
Grant Description

Over 400 million people globally suffer from back pain. Disc degeneration disease is the prevalent cause of back pain and it is responsible for high social and economic costs.

Current treatments are only symptomatic (physiotherapy, pain management or surgery), but they do not regenerate the disc and its function.At NC Biomatrix, we have developed VitaDisc, the first non-invasive early restorative treatment for disc degeneration that has the power to revolutionise the orthopaedics market.

It is an acellular porcine-derived injectable biomatrix that restores disc height, provides optimal support to regenerate the disc, and aids in restoring healthy spinal biomechanics.

Its mode of action is fully mechanical, and it can be easily administered in an outpatient setting, giving it a unique market advantage.Our biomatrix platform technology is readily scalable and provides a pipeline of further products for unmet needs in orthopaedic treatments, such as early-stage knee joint arthritis.

All Grantees

Nc Biomatrix Bv

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant